Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020

Web Exclusives

Although medical cannabis has been used successfully as a palliative therapy in patients with cancer, it is still stigmatized because of its illicit scheduling. However, as research on cannabis use in oncology matures and the stigma begins to fall away, more states are allowing for pharmacist oversight of this product, and its legalization continues to spread.

Compelled by the current lack of standardization, the International Society of Cannabis Pharmacists (ISCPh) was founded to recognize the legitimate use of medical cannabis and unify the pharmacy profession on this topic to support public health.

With an ever-growing membership of approximately 300 licensed pharmacists, medical professionals, and industry leaders in the United States and abroad, the ISCPh seeks to advance cannabis education and collaboration and empower pharmacists to responsibly administer cannabis to appropriate patients.

According to Jeffrey Lombardo, PharmD, BCOP, Secretary of the Board of Directors of the ISCPh, it is becoming increasingly important for pharmacists to educate themselves on the medical use of cannabis in oncology.

In this interview with Value-Based Cancer Care (VBCC), Dr Lombardo discusses the mission of the ISCPh, and plans for the organization's inaugural meeting.

VBCC: What is the mission of the ISCPh?

Dr Lombardo: Our mission is education, centering around the role of the pharmacist as it relates to the management of cannabis as a medication. As a pharmacist and a researcher, I am concerned about safety first and efficacy second. There is credible evidence that certain drug–drug interactions can lead to serious adverse events.

For example, Epidiolex is a pure cannabidiol (CBD) isolate and the first FDA-approved prescription cannabinoid medication for the treatment of 2 forms of epilepsy. Safety data from studies have shown that this drug has the potential for causing elevated liver enzyme levels and could be hepatotoxic at higher doses. Therefore, careful monitoring of the patient is a clinical function that should be done by the pharmacist while patients are receiving this medication.

We need to set level expectations up front. At the end of the day, cannabis can be associated with certain side effects, and the product is not effective for everyone who tries it at the initial starting dose. When cannabis is combined with a patient’s established medication regimen, there can be a synergistic effect, both positive and negative.

VBCC: What is the role of the pharmacist in this area?

Dr Lombardo: Each state has its own protocol for a medical marijuana program, and in some states, pharmacists are not even involved in the process. In New York State, the process relies heavily on pharmacist input. For instance, a medical provider can give the patient a recommendation for cannabis, but if the provider is not specific, the pharmacist may select the product and dosage, and then provide the necessary education on its use.

The pharmacist’s primary role is to perform a drug–drug interaction check and look for potential clinical contraindications to the product, followed by a discussion with the patient on the therapeutic benefits of cannabis, as it relates to the patient’s specific qualifying condition.

I spend 1 day every other week working in a dispensary in New York, because I am interested in knowing which questions patients have about dosing, how they respond to the products, and how we are following up with them. This has allowed me to create a program where relevant clinical information is communicated back to a select group of medical providers. This is truly a multidisciplinary approach and has resulted in a program that benefits all parties involved. Not all patients respond positively to cannabis and you need to know when to move on to another form of therapy.

VBCC: What is the goal of the ISCPh inaugural meeting?

Dr Lombardo: The meeting is focused on awareness, education, and networking. For example, labeling standards are a big focus for us as an organization. Not every state provides the same clear, concise information on its product labels. We plan to initiate discussions and form a national working group that focuses on what needs to be studied over the next year in relation to research, policy, and clinical practice.

Clinical research on cannabis has increased since the passage of the 2018 Farm Bill, and we are working on bringing individuals with regulatory knowledge and experience to the meeting to comment on this bill. I will be moderating a session on the future of cannabis pharmacy. A panel of physicians, researchers, and pharmacists will discuss what needs to be done collaboratively as we move forward.

VBCC: Why is it crucial for providers to be informed about cannabis?

Dr Lombardo: Patients are trying it, they are using it, and it is everywhere. They are more open to alternative medicine and state regulations are changing to allow it. If you look at the number of growers, processors, and distributors within the CBD market alone, it has increased exponentially in recent years.

I work very closely with patients enrolled in palliative care programs and have done so for more than 20 years. Cannabis does help some of these individuals, and for some, it has helped tremendously.

I know that most of this information is currently not evidence-based; however, in my daily contact with patients, I have seen cannabis help with symptom control in numerous individuals with cancer. However, for patients on active treatment, it can be a different story; you need to look at potential drug–drug interactions and the possibility of increased toxicities associated with potent anticancer medications.

VBCC: What are the safety issues to consider?

Dr Lombardo: Cannabis is metabolized through the liver, as are many other FDA-approved drugs. A pharmacist needs to obtain a complete medication history from the patient, and a plan should be put in place to monitor for potential side effects.

For example, a patient who obtained a certification for medical cannabis via the Internet recently came into the dispensary. This individual was seeking relief for general pain syndrome. During my interview with him, I discovered that he was taking an immunosuppressant medication and was also a kidney transplant recipient. Some of his medications would have directly interacted with CBD, so I did not dispense a product to him that day.

Instead, I provided education, along with a strong recommendation that he speak to his local transplantation physician and tell him what he wanted to do regarding cannabis therapy. If they decided as a team that it was okay for him to try it, his monitoring regimen would have to be vigorously modified for a potential fluctuation of immunosuppressant levels.

In certain subsets of patients, we need to carefully consider the risk–benefit ratio and determine whether there are other options for pain relief. There are also specific medical conditions for which cannabis use would not be recommended.

VBCC: How will the increasing use of cannabis affect providers and policymakers?

Dr Lombardo: Providers need to be engaged because patients with cancer are using alternative medications, cannabis included. They need to develop a better understanding of cannabis and its treatment options. As usage continues to evolve, policymakers need to clarify their stance on the state and federal laws. Their constituents may begin to demand changes to current laws, and they will need to be open to renegotiating some of the current procedures as patient treatments change.

Related Items
What’s New in the Oncology Drug Pipeline?
Meg Barbor, MPH
JHOP - June 2020 Vol 10, No 3 published on June 22, 2020 in HOPA Highlights, Novel Pharmaceuticals
The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer
Meg Barbor, MPH
JHOP - June 2020 Vol 10, No 3 published on June 22, 2020 in HOPA Highlights, Biomarkers, Immunotherapy, Lung Cancer
The Cancer Care Gap in Rural America: A 50-Million People Conundrum
Meg Barbor, MPH
JHOP - June 2020 Vol 10, No 3 published on June 22, 2020 in HOPA Highlights, Disparities in Oncology
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in Multiple Myeloma
Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in NCCN News
What Is the Role of Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukemia?
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in Leukemia, NCCN News
Formal Hereditary Cancer Genetics Counseling Improves Patient Outcomes
Meg Barbor, MPH
Web Exclusives published on November 7, 2019
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
HOPA Encourages Oncology Pharmacists to Deliver Patient Outreach Services
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in HOPA Highlights
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in Breast Cancer, HOPA Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.